- Conditions
- Type 2 Diabetes
- Interventions
- Sitagliptin, Basal Bolus, Metformin and Sitagliptin, Glargine, Glargine 50%, Glargine 80%
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Ann Arbor, Michigan • Columbus, Ohio + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 73
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus
- Interventions
- MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]), CSII (Animas Corporation insulin pump, model IR 1200)
- Drug · Device
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 24 more
- Conditions
- Hyperglycemia
- Interventions
- Human regular insulin, Insulin lispro, Insulin glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 9 more
- Conditions
- Diabetes Mellitus
- Interventions
- Regular Human Insulin, Lispro, VIAject, VIAject 50%, VIAject/Insulin Glargine, Insulin Glargine/VIAject
- Drug
- Lead sponsor
- Biodel
- Industry
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin Glargine, Insulin Aspart, Insulin Lispro
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- South Miami, Florida
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin lispro, Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Concord, California • Fresno, California + 30 more
- Conditions
- Diabetes in Pregnancy, Gestational Diabetes
- Interventions
- Insulin glargine alone, Insulin glargine + insulin lispro
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey • New York, New York
- Conditions
- Hyperglycemia
- Interventions
- Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec, Metformin, SGLT2 inhibitor
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 933 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 32
- States / cities
- Fresno, California • La Mesa, California • Lancaster, California + 26 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Dapagliflozin, Insulin, Liraglutide, Dapagliflozin placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Diabetes Mellitus, Type 1 Diabetes
- Interventions
- Rapid-Acting Insulin, Long acting insulin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 7 Years to 15 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- premeal insulin lispro mixtures, insulin glargine, metformin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Interventions
- Afrezza, Rapid-acting Insulin Analog, Basal Insulin
- Biological
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 39
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 35 more
- Conditions
- Diabetes Mellitus
- Interventions
- Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- NPH and regular insulin, glargine and humalog
- Drug
- Lead sponsor
- Riverside University Health System Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Moreno Valley, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Exenatide-LAR plus Dapagliflozin placebo, Exenatide-LAR plus Dapagliflozin, Insulin Titration, Behavioral Therapy
- Drug · Behavioral
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin
- Drug · Other · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Type 2 Diabetes
- Interventions
- Linagliptin, Basal Bolus, Linagliptin + 50% Glargine dose on discharge, Linagliptin + 80% Glargine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 1 more
- Conditions
- Type 2 Diabetes
- Interventions
- Insulin Glargine, Metformin, Prandial insulin, Exenatide
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 12
- States / cities
- San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin glargine (HOE901), Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 1 Year to 6 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 8
- States / cities
- Sacramento, California • San Diego, California • Greenwood Village, Colorado + 5 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Glargine, LY2605541, Insulin Lispro
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 47
- States / cities
- Concord, California • Fresno, California • La Mesa, California + 44 more
- Conditions
- Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia
- Interventions
- Sitagliptin, glargine, lispro
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- SAR342434, Humalog, Insulin glargine HOE901
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 47
- States / cities
- Tucson, Arizona • Bell Gardens, California • Chula Vista, California + 36 more